Profil bibliographique

Alan V. Boddy

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

273Publications signalées

7917Citations signalées

2Affiliations récentes

Institutions déclarées

Domaines associés

Chemotherapy-induced organ toxicity mitigationNeuroblastoma Research and TreatmentsCancer therapeutics and mechanismsCancer Treatment and PharmacologyAcute Lymphoblastic Leukemia research

Publications récentes

Accès ouvert 2025 articleOpenAlex

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib

Alan V. Boddy, Andrew J. McLachlan, Jeffry Adiwidjaja, Josephine A. Adattini

0 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)

Accès ouvert 2025 articleOpenAlex

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

Geeta Sandhu, Josephine A. Adattini, Evangeline Armstrong Gordon, Niamh O’Neill et autres

8 citationsEClinicalMedicine

Accès ouvert 2025 articleOpenAlex

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL

Harry Iland, John Reynolds, Alan V. Boddy, Hayley B. Schultz et autres

5 citationsBlood Advances

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Figures 1 and 2 from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Figures 1 and 2 from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Figure 1 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Figure Legend from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Figure 2 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Rachel Daniel, Agata Rozanska, Huw D. Thomas, Evan A. Mulligan et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.